Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting (GlobeNewswire) - Jun 29, 2023 - P1/2 | N=55 | ReSPECT-GBM (NCT01906385) | Sponsor: Plus Therapeutics | "Plus Therapeutics, Inc...today reported positive interim updates from the ReSPECT-GBM and ReSPECT-LM...at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting, which took place June 24-27, 2023 in Chicago, Illinois....The data demonstrates efficacy signals in a prognostically unfavorable patient population. The median overall survival (OS) in all 21 patients (including those receiving small radiation doses in early cohorts and five patients previously treated with Bevucizamab) was 11 months or a 38% increase in OS versus a median OS of approximately 8 months for standard of care in rGBM. Median OS in patients receiving >100 Gy of absorbed radiation dose was 76 weeks (17 months) versus 22 weeks (6 months) for those receiving <100 Gy (p=0.0002)."
P1/2 data • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|